A new type of fluoroquinolone antibiotic that achieves its antibacterial effect by inhibiting the activity of bacterial DNA gyrase and topoisomerase IV, thereby hindering bacterial DNA replication. It is effective against aerobic bacteria, anaerobic bacteria, Gram-positive bacteria and Gram-negative bacteria. It has a killing effect on Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus, and has strong antibacterial activity against certain drug-resistant bacteria.

In vitro studies have shown that actinomycin D mainly acts on RNA, and at high concentrations affects both RNA and DNA synthesis. The mechanism of action is that it is embedded in the DNA double strand and binds to its guanine group, inhibiting the activity of DNA-dependent RNA polymerase, interfering with the transcription process of cells, and thus inhibiting mRNA synthesis. It is a non-specific drug for the cell cycle, and is particularly sensitive to the G1 phase, preventing G1 phase cells from entering the S phase.

No specific information provided

This product is a drug that promotes the metabolism of central nervous cells. Its mechanism of action is that the active thiol groups released in the body participate in the redox process of brain cells, thereby promoting and restoring the metabolism of brain cells and quickly restoring metabolic function. In addition, it also has the effect of counteracting central nervous system drugs.

This product is a drug that promotes the metabolism of central nervous cells. Its mechanism of action is that the active thiol groups released in the body participate in the redox process of brain cells, thereby promoting and restoring the metabolism of brain cells and quickly restoring metabolic function. In addition, it also has the effect of counteracting central nervous system drugs.